1042 results about "Bile fluid" patented technology

A device for performing one or more functions in a gastrointestinal tract of a patient includes an anchoring member and at least one actuator, sensor, or combination of both coupled with the anchoring device. The anchoring device is adapted to maintain at least part of the device within a pyloric portion of the patient's stomach and to intermittently engage, without directly attaching to, stomach tissue. Actuators perform any suitable function, such as transmitting energy to tissue, acting as a sleeve to reduce nutrient absorption, occupying space in the stomach, eluting a drug and/or the like. Sensors may be adapted to sense any suitable patient characteristic within the patient's gastrointestinal tract, such as pH, temperature, bile content, nutrient content, fats, sugars, alcohol, opiates, drugs, analytes, electrolytes and/or hemoglobin.

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

Aspects of the present disclosure include a surgical device comprising electrodes on the sides of an end of an effector to aide in sealing during various surgical procedures, such as a liver resection. During a sealing procedure, the surgeon may wipe the surgical site with the end effector, causing the electrodes to touch the fractured area. Electrosurgical energy may be applied to the electrodes during the wiping, causing coagulation of smaller vessels, such as tiny blood vessels and bile ducts in the parenchyma of the liver. In some cases, due to the nature of some smaller vessels, electrosurgical energy should be delicately applied to cause sealing but to avoid overly damaging the remaining tissue. In some embodiments, the thin design of the electrodes allows for an appropriate amount of electrosurgical energy to be applied to the fractured area.

A single, integrated device in which a body fluid (e.g., blood) of a human or animal can be both collected and analyzed easily and without risk of contamination is disclosed. The collection portion and analysis portion of the device are permanently joined to permit movement of small quantities of body fluid under controlled conditions, to minimize any waste of the body fluid, to ensure that no contamination reaches the main body fluid volume, and to create a permanent physical record of the results of the analysis in association with the fluid sample itself: A wide variety of different body fluid components which may be indicative of various diseases, dysfunctions and abnormalities of the human or animal or the body fluid itself can be tested for. The device includes a container for collecting human or animal body fluid, one or more testing chambers containing one or more analysis units activated by body fluid; a transfer pump or vacuum assembly to transfer one or more samples into the analysis units; and one-way valves or the equivalent to prevent any portion of the withdrawn sample from being returned to the collection container. The body fluid acted upon may be blood, blood plasma, urine, bile, pleural fluid, ascites fluid, stomach or intestine fluid, colostrom, milk or lymph.

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions are disclosed. Compositions of the disclosure may comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further contain a pharmaceutical compound in a pharmaceutically effective amount. The disclosure further provides dried forms of primary aqueous solubilized bile acid formulations and methods of preparing such dried forms.

The invention discloses a decellularized pericardial tissue via chemical treatment with cholic acid or bile salts as a medical device and process of manufacture.

There is provided a method for controlling the movement of bile and/or gall stones in the biliary duct. The method comprises gently constricting (i.e., without substantially hampering the blood circulation in the tissue wall) at least one portion of the tissue wall to influence the movement of bile and/or gallstones in the biliary duct, and stimulating the constricted wall portion to cause contraction of the wall portion to further influence the movement of bile and/or gallstones in the biliary duct. The method can be used for restricting or stopping the movement of bile and/or gallstones in the biliary duct, or for actively moving the fluid in the biliary duct, with a low risk of injuring the biliary duct.

Disclosed herein are three-dimensional porous tubular scaffolds for cardiovascular, periphery vascular, nerve conduit, intestines, bile conduct, urinary tract, and bone repair/reconstruction applications, and methods and apparatus for making the same.

The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier.

The invention discloses a valved stent and process of manufacture for treating chronic venous insufficiency having the geometry of the supporting frame and its coupling to the membrane of a specific geometry that provides the valvular mechanism for optimal function. The membrane may comprise a decellularized pericardial tissue via chemical treatment with cholic acid or bile salts and crosslinked.

Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further contain a pharmaceutical compound in a pharmaceutically effective amount. Non-limiting examples of pharmaceutical compounds include insulin, heparin, bismuth compounds, amantadine and rimantadine.

The invention relates to a traditional Chinese medicine for treating cardiac, cerebral and vascular diseases; the drug is composed of forty kinds of crude drugs by weight parts: milk veteh, salvia miltiorrhiza, root of common peony, ligusticum wallichii, lumbricus, sanguisuga, rhizoma acori graminei, polygala root, red ocher, oyster, angelica, the root of kudzu vine, arisaema cum bile and the like; the preparation method is that: (1) the crude drugs are prepared into water extract liquid; (2) the water extract liquid is prepared into oral liquid; (3)the water extract liquid obtained by the step (1) is dried, crushed, sieved, undersize material is extracted powder; (4) the extracted powder prepared by the step (3) is prepared into various dosage forms. The preparation method of crude powder is that: lime earth of the crude drugs is sieved, and then the crude drugs are crushed and sieved, the undersize material is taken out and is sterilized to be crude powder, and the crude powder is prepared into various dosage forms. The traditional Chinese medicine has the major functions of treating miocardial infarction and angina caused by coronary heart disease, high blood pressure and cerebral thrombosis, hemiplegia, cerebral infarction, cerebrovascular accident, sequel of apoplexy and other symptoms, and the medicine has obvious effect on headache, dizziness and heart cerebrovascular diseases caused by high blood pressure and cerebral circulation insufficiency.

A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include α-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An illustrative delivery agent is N^α-deoxycholyl-L-lysine-methylester. The delivery agent and the biologically active agent are mixed together to form a complex, which is then administered to the animal. These complexes are particularly useful for oral administration of biologically active agents, but other routes of administration may be used.

Lactobacillus rhamnosus and the use for it and its metabolin are disclosed. The strain is sieved and obtained from excrement of long-lived old. It's safe, has excellent antibacterial, acid-resisting and antioxidant performances. It can be used in dairy process and functional food production.

The present invention, in an exemplary embodiment, provides a stent, which combines many of the excellent characteristics of both silicone and metal stents while eliminating the undesirable ones. In particular, a principal objective in accordance with the present invention is to provide a family of stents generally and a biliary stent in particular where the relative hardness/softness of regions of the stent can differ from other regions of the stent to provide additional patient comfort and resistance to radial forces. An exemplary embodiment also provides a family of stents with novel interstice configurations that facilitate flexibility, durability and/or proper installation. Additionally, the biliary stent in accordance with the present invention provides enhanced flow mechanics to ensure the adequate clearance of viscid fluids such as bile.

The present disclosure relates to methods and compositions to offset, ameliorate and/or alleviate one or more unwanted and/or adverse gastrointestinal effects. For example, in some embodiments, the present disclosure relates to compositions that include a bile acid, a carbohydrate and/or a pharmaceutical compound, wherein the pharmaceutical is associated with an adverse gastrointestinal effect in a subject (e.g., mammal or human). Non-limiting examples of pharmaceutical compounds may include a nonsteroidal anti-inflammatory drug, a gastric irritating drug (e.g., an antibiotic, an adrenal cortocoid steroid and an anti-cancer drug) and combinations thereof. The disclosure further relates to methods of ameliorating or eliminating at least one adverse gastrointestinal effects of a composition, comprising administering to a subject an aqueous solution comprising a bile acid and a carbohydrate.

The invention discloses a preparation method for bear bile powder, and relates to the technical field of medicine preparation. The preparation method comprises the following steps: filtration: obtaining fresh drained bear bile, and carrying out filtration to obtain a filtrate; sterilization: adding high-concentration ethanol into the filtrate till the ethanol content of a liquid medicine reaches 75-85%, and then carrying out 20-40 minutes' stirring and 24-72 hours' still standing; concentration: carrying out vacuum concentration to remove ethanol and obtain sterilized bear bile; freeze drying: conducting freeze drying on the sterilized bear bile. According to the preparation method, the characteristic that fresh bear bile is a liquid is adopted, so that ethanol and the fresh bear bile are miscible; the function of ethanol to kill viruses and pathogens is adopted, so that various pathogens and viruses can be killed through control of the content and existence time of ethanol in the liquid medicine, active ingredients in the bear bile are protected from damage; the safety and availability of clinical medication are guaranteed, and the defects in the conventional bear bile powder production process are overcome; the prepared bear bile powder is golden yellow in appearance and transparent in luster; through adoption of the preparation method, the quality of the bear bile powder is greatly improved.